Buck Institute for Research on Aging 2014 Annual Report

15 YEARS

leading the way 2014 ANNUAL REPORT

leading the way 2014 ANNUAL REPORT

the buck index 1999–2014 2003 Julie Andersen links iron to Parkinson’s disease in the cover story of the journal Neuron.

September 30, 1999 The Buck Institute officially opens its doors with President & CEO Dale Bredesen, MD, at the helm.

1999

2000

2000 Simon Melov and Gordon Lithgow report the first successful use of a drug-like compound to extend lifespan in an animal. The study is published in Science.

2006 In results published in The Proceedings of the National Academy of Sciences, the Bredesen lab genetically engineers “Alzheimer’s” mice that have normal memory despite the presence of amyloid plaques in their brains.

2006 The Institute’s first capital campaign concludes with the establishment of the Larry L. Hillblom Center for Integrative Studies of Aging.

2003 The Institute’s auditorium is named for Trustee Fred Drexler in honor of his $3 million gift to the Institute.

2001

2002

2003

2004

2006 The Institute’s first patent is awarded to Dale Bredesen, MD, and others for “Modulators of Paraptosis and Related Methods.”

2005

2006

2007 A $25 million “Roadmap” award from the NIH establishes a new field of research called “geroscience,” which will focus on the intersection of aging and chronic disease.

The Buck’s award is one of only nine granted in the country.

CAMPISI ZENG

BENZ Cancer Biology GIBSON

2006 Christopher Benz, MD, in partnership with the Marin Department of Health and Human Services, helps launch the Marin Women’s Study.

Biochemistry

Proteomics

Stem Cell Biol

HUGHES Genetics

GILL

Nutrition

Chemical Biology

Bi Neuroscience

Invertebrate Biology

LITHGOW

G

MELOV

ANDERSEN

VIJG

2007 In a study published in PLoS One, the Melov lab shows that strength training reverses aging in human skeletal muscle.

2007 A grant of $4.1 million from the California Institute of Regenerative Medicine (CIRM) establishes a shared research laboratory for stem cell technology at the Institute.

2007

2008

2009 In a study published in Nature Cell Biology, Judith Campisi establishes the basis for research on “inflammaging” by showing that DNA-damaged cells communicate with neighboring cells.

2009

GREENBERG

logy NICHOLLS

ELLERBY

ioenergetics

BREDESEN

2010

2011

2011 Douglas Rosenberg invests $3.5 million to fund drug development efforts in the Bredesen lab.

2008 CIRM awards the Buck Institute $20.5 million in seed money to build a new facility for stem cell research.

2009 Publishing in Cell, Pankaj Kapahi shows that a low-protein “antiAtkins” diet extends lifespan in fruit flies.

2011 Publishing in Nature, the Lithgow lab reveals that a common laboratory dye profoundly extends lifespan and slows the disease process in nematode worms with Alzheimer’slike pathology.

2010 Brian K. Kennedy, PhD, is appointed the Buck Institute’s second president & CEO.

2010 CIRM awards the Zeng lab $6 million to develop a stem-cellderived treatment for Parkinson’s disease.

2012 Board member Arthur Gensler Jr. and his wife, Drue, donate $5 million to the Buck.

The Institute’s administra­ tive building is renamed in their honor.

2012

2012 The Institute spins off its first company, Delos Phar­maceuticals, Inc.

2012 The Buck opens its second research building on April 14.

More than 1,000 people attend an open house celebrating the new Regenerative Medicine Research Center.

2013 The Institute opens its new Learning Center. Its mission is to foster young scientists and encourage life-long science education.

2013

2014

2013 The Melov and Kennedy labs publish research in Aging Cell that shows the drug rapamycin reverses heart disease in elderly mice.

2014 The Buck Institute and the University of Southern California collaborate to launch the nation’s first PhD program in the biology of aging.

Genomics

KAPAHI

Buck Institute 2014 Annual Report 3

Letter from CEO Brian Kennedy and Board Chair Larry E. Rosenberger

W

e are extremely proud to celebrate our 15th anniversary. Since its inception, the Buck Institute has been leading the way in viewing aging not just as an inevitable consequence of time but as a biological process that can be described, and modified, in order to stem the tide of chronic disease. We named this study “geroscience,” a term that has been adopted by the National Institutes of Health, is used in Congress, and is now understood globally.

Geroscience is what makes the Buck unique. We bring scientists from disparate fields together and unite them with one common focus—to extend human healthspan. Our pioneering approach is gaining momentum, evidenced by the growing number of the Buck’s scientific collaborations with scores of other leading institutes locally, nationally, and internationally (see map, page 14).

Brian Kennedy and Larry Rosenberger

An outstanding example of our approach is the Buck Aging Intervention Testing (BAIT) project, which was launched this year. BAIT is the most comprehensive project in the world to attempt to map, and then improve, healthy aging in mammals. This research is leading the way by providing a desperately needed bridge between mice and humans that will ultimately lead to the clinical testing of drugs to improve healthy aging. Described as a game changer by others in the field, BAIT has become a major focus of our fundraising efforts.

Education, both of young scientists and the public, is central to our mission. With the launch of the nation’s first PhD Program in the Biology of Aging, which we established in collaboration with the University of Southern California, as well as our community outreach, we now have education from “K-to-grey” and are implementing various plans to bring engaging science education to local schools.

Celebrating our 15th anniversary gives us an opportunity to reflect on our past achievements and to look to what we want to be in the future—a major player in the revolution from sick care to health care. This comes at a time when we fully expect that federal funding will remain flat for many years to come.

Even though our scientists continue to receive highly competitive awards from the National Institutes of Health, we must reduce our dependency on government funding. At the Buck, we are focused on diversifying our revenue and increasing our collaborations with industry and global partners.

We are also intent on changing the erroneous perception that our financial stability is guaranteed by our relationship with the Buck Trust. While the Trust is an important part of our history, in this past year just 17.5 percent of our revenues came from that source.

Our visionary research is fueled by, and is dependent on, the support of our individual donors as well as our corporate and foundation sponsors. We are extremely grateful for these contributions and hope that you will continue to support our cause—keeping people healthier, longer. In our rapidly aging society, this issue has never been more important.

Brian K. Kennedy, PhD President and Chief Executive Officer

4 Buck Institute 2014 Annual Report

Larry E. Rosenberger

Chair, Board of Trustees

The Buck Index 2014

leading the way

2

CEO Brian Kennedy on What’s Ahead for Research on Aging There’s No Stopping Geroscience Buck Faculty

6

9

10

Year in Review

12

Celebrating Our History

2014 Board of Trustees

28

Scientific Advisory Board Buck Advisory Council Financial Summary

29

30

32

25

Cumulative Donors

32

Cumulative Sponsors

33

Honor Roll of Donors

33

Buck Staff

36

Buck Institute 2014 Annual Report 5

What’s Ahead for Research on Aging?

CEO Brian Kennedy on the Future of the Buck What direction is the Buck Institute headed in?

Brian Kennedy: Aging research used to be a pretty insular affair—not many people wanted to talk to us. That’s changed dramatically in the past few years. The aging field is hot right now, and as the nation’s first independent research institute to focus solely on the connection between aging and chronic disease, we very happily wear the mantle of leadership in the field. Not only are we doing great science and beginning to develop drugs for the diseases of aging, we’re also on the front lines of promoting healthspan vs. lifespan.

We think we’ll be able to give people an extra decade of good health—that’s our focus. The public as well as physicians, public health officials, pharmaceutical executives, and those in other research disciplines are starting to appreciate the science behind aging and to understand the urgency of our mission.

But it’s not all smooth sailing, is it?

No, it’s not. There’s a lot of promise, but also a lot of frustration. The nonprofit medical research system is going to break in the United States unless there’s a renewed commitment from the government to support it, and I’m not seeing any signs of

6 Buck Institute 2014 Annual Report

that right now. We’re seeing major research institutions pushed to the brink of bankruptcy. Unless they have access to massive financial resources, I am not sure that long-term financial sustainability can be assured.

We have to find ways to grow in this environment because global aging is happening now.

That means we need to expand our important research by getting more grants, increasing philanthropic support, and finding new ways to bring in resources. We will never run away from our mission to extend healthspan and perform highly impactful aging research, and we will continue to be competitive for NIH grants, but we also have to be realistic that there’s little sign that the NIH budget is going increase anytime soon. We must be creative and find the paths that ensure financial sustainability and growth into the future.

How important are our global partnerships to the future of the Buck?

Aging is a global problem. There are countries where the percentage of people over 65 will approach 40 percent in the near future. At the Buck, we need to raise global awareness and build a research network to understand and deal

Brian Kennedy with lab aide Christine Robbins

with aging, rather than trying to conquer this huge burden individually. I think that’s a perfect strategy going forward. If you want to look at ways other countries can cooperate in a meaningful way, why don’t we pick the next pandemic and prevent it?

Aging is the top candidate. We want to promote

As we learn more about the molecular and genetic markers of aging, we need to have strategies to test them in the clinic. Right now people go to the doctor when they’re sick. We need people to go when they’re healthy so that we can catch the first changes that suggest that someone is starting to head down the wrong path. We already know what some of those things are, and the list of indicators of health and biomarkers of aging likely will continue to expand.

We also need to start thinking about how to intervene with people who are still healthy, with the goal of keeping them healthy for as long as possible.

This could involve everything from natural products to drug interventions to healthy diets and lifestyle.

Essentially, I believe an effective program to extend healthspan ultimately will involve combined strategies that are personalized to the individual—a personalized approach to offset personal aging.

That’s going to require some massive changes, won’t it?

that effort—to continue training people from Kazakhstan, partnering with institutes in Russia, thinking about the problems that are unique to China, and interacting with researchers in Korea, Chile, and throughout the world.

Yes, in addition to the crisis in federal research funding, the medical field is going through a huge transition right now. The impact of the Affordable Care Act will be large and unpredictable, especially over the next few years. If we can get people insured, it’s a great thing, and if we can reimburse prevention, that’s a great thing. But any time you make a major shift in the landscape, you get unpredictable fallout. Everywhere we look there’s unpredictability and stress.

We also need to figure out how to bring global resources together in a way that allows us to do something really revolutionary—convert medicine from sick care to healthcare. There are many opportunities where institutions can partner in ways that promote each other’s goals, and we must continue to seek them out.

But I’m still very optimistic. We’re trying to bring about a revolution, and there is no way to do that without upheaval. We’re trying to go from sick care to healthcare. It’s the right thing to do. It’s costeffective and it improves quality of life. It’s the right argument for 20 different reasons, and people are beginning to recognize the potential.

Brian Kennedy discusses research with Buck faculty Gordon Lithgow, PhD, and postdoc Daniel Edgar, PhD.

How do you envision the future of aging itself?

How do we get there?

We need a broad spectrum of changes. We need to be promoting healthy lifestyles. I don’t care if you’re 10 or 15 or 25 or 30 or 50 or 70, that’s got to be done. That’s the starting point.

8 Buck Institute 2014 Annual Report

At the Buck, we’re doing our best to make the science go forward as quickly as possible while we go through this transitional crisis. We are going to emerge from it stronger and grow in ways that promote the extension of healthspan. The best way to predict the future is to create it.

and exploit links between aging and chronic disease. Initial partners include geriatricians and basic scientists from the Buck Institute, Mayo Clinic, Barshop Institute, Albert Einstein College of Medicine, and Stanford University School of Medicine; Harvard, Johns Hopkins, and Wake Forest Universities; and the Universities of Washington, Arkansas, Minnesota, and Michigan.

pisi

Geroscience at the Buck Institute Geroscience was conceived and nurtured at the Buck Institute and continues to grow in scope. Sharing an intense focus on the link between aging and chronic disease, Buck faculty collaborations are bringing together the biology of normal aging and the origins of chronic diseases.

a

Cam

Benz

Activity at the National Level The first Geroscience Summit, held on the campus of the National Institutes of Health (NIH), involved Buck scientists, representatives from 20 NIH institutes, and researchers from across the country. The focus was on understanding the impact of aging on healthspan and chronic disease.

The NIH funded a grant to establish a national interdisciplinary network of aging centers as the basis for a Geroscience Network to understand

Lamb

on

Ze

bs

ng

Gi

Ke n

Cancer Biology

dy

b en

re

G

Stress Biology

Hu

g

er

ne

Proteomics

on

rris

ghe

Ga

s Nutrition

Genetics

Mammalian Aging

Stem Cell Biology

Brand

lls Nicho

Biochemistry Bioenergetics

Physiology

Lithgow

Brem

Genomics

Chemical Biology

Metabolomics

ov Mel

Neuroscience

ak

ny

Epigenomics

rby

Ha

gh

Bioinformatics Invertebrate Biology

igh

i

Br

er

e ed

Andersen

y

n se

ahi Kap

an

Ramanath

Mo one

Lu

Elle

Metallomics

sp

ncer logy

Geroscience is the new scientific discipline that spans the biology of aging and age-related disease. Based on the idea that aging itself is the major cause of the diseases of aging, geroscience took on a life of its own this year. Coined by the Buck, the term cropped up in congressional briefings and in the agendas of national organizations.

Ja

ncer logy

There’s No Stopping Geroscience

Buck Institute 2014 Annual Report 9

Buck Faculty Julie K. Andersen PhD, Professor

Targeting cell death in Parkinson’s disease, identification of novel therapeutics

Dale Bredesen

Chris Benz

MD, Professor Bench-to-bedside and community efforts to reduce breast cancer incidence and improve patient outcomes

Rachel Brem

Judith Campisi

Understanding how and why traits related to longevity and the diseases of aging differ between individuals

Senescence-related mechanisms that link tumor suppression and the development of cancer to aging and the major diseases that are associated with aging

Jennifer L. Garrison

Bradford W. Gibson PhD, Professor

David Greenberg

PhD, Assistant Professor

Uncovering the role of neuropeptides in aging and disease

Understanding the biological and chemical processes that are common to both agerelated diseases and aging

Vascular and neuronal mechanisms in stroke

MD, Professor

Mechanisms of Alzheimer’s disease and potential therapeutics

PhD, Associate Professor

10 Buck Institute 2014 Annual Report

PhD, Professor

MD, PhD, Professor

Martin Brand PhD, Professor

Altered energy metabolism and radical production in aging and disease

Lisa Ellerby

PhD, Associate Professor Understanding the pathways that lead to nerve cell death in Huntington’s disease and other neurodegenerative disorders

Pejmun Haghighi PhD, Professor

Tuning neural function as it relates to aging and agerelated diseases

Robert Hughes

PhD, Associate Professor Understanding the mechanisms of aging and neurodegeneration in healthy adults and in people with disorders such as Huntington’s disease

Deepak A. Lamba MBBS, PhD, Assistant Professor

Development of stem cell technologies for treating vision disorders

Sean D. Mooney

PhD, Associate Professor Using computers to enable the next generation of biomedical research

Heinrich Jasper PhD, Professor

Enhancing stem cell function to promote longevity

Gordon Lithgow PhD, Professor

Uncovering genes and small molecules that prolong lifespan through enhanced molecular stability

David G. Nicholls PhD, Professor

Mitochondrial function and the life and death of cells

Pankaj Kapahi PhD, Professor

Understanding the role of nutrition and energy metabolism in lifespan and disease

Victoria Lunyak

PhD, Associate Professor Understanding the epigenetic principles of human adult stem cell aging

Arvind Ramanathan

PhD, Assistant Professor Molecular physiology of skeletal muscle regeneration, aging, and the formation of tumors

Brian K. Kennedy

PhD, Buck Institute CEO and Professor Moving research in aging from simple organisms into mammals to improve human health

Simon Melov PhD, Professor

Identifying molecular hallmarks of aging to guide the development of anti-aging therapies

Xianmin Zeng

PhD, Associate Professor Developing stem-cell-based treatments for neurodegenerative disorders

Buck Institute 2014 Annual Report 11

year in review New Grants and Published Research TOP FOUNDATION GRANTS • $200,000 from Part the Cloud/Alzheimer’s Association to Dale Bredesen to help fund a clinical trial in Australia.

• $150,000 from the Progeria Research Foundation to Brian Kennedy for small-molecule testing in mouse models of progeria, a disease characterized by premature aging.

3 Image of human light-sensing cells inside a mouse eye

TOP GRANTS FROM THE NIH • $2.9 million for a 5-year grant to Gordon Lithgow for “The Pharmacology of Lifespan Extension,” research to identify the mechanism of action of compounds that delay the onset of age-related pathologies and extend lifespan in animal models.

• $2.1 million 5-year grant to Pejmun Haghighi for “Retrograde Regulation of Synaptic Strength by Translational Methods,” research to unravel molecular components and mechanisms that maintain stability in neural circuits.

• $1.7 million to Gordon Lithgow, Simon Melov, Pankaj Kapahi, and collaborators at Rutgers University and the University of Oregon for “Discovering Compounds with Robust Pro-Longevity Activities.” Researchers are developing sorely needed standard operating procedures for compound screening in Caenorhabditis elegans (C. elegans). An “automated lifespan machine” has been built at the Buck. 1 • $755,000 to Jennifer Garrison to explore neuropeptide signaling in C. elegans. Neuropeptides are one of the major signals used by neurons to modulate behavior and physiology, and neuropeptide receptors are important targets for the treatment of disease. 2 • $200,000 to Campisi lab postdoctoral fellow RemiMartin Laberge, the recipient of a highly coveted and competitive K-99 award that provides federal funding to transition promising postdocs to running their own lab as a faculty member. Laberge’s research is focused on inflammation and aging.

12 Buck Institute 2014 Annual Report

• $120,000 from the Foundation for Retinal Research to Deepak Lamba to study long-term survival of stem-cell-derived photoreceptors in mice suffering from retinal deterioration. 3

2 A 3D model of the C. elegans connectome (map of neural connections) from the Open Worm Project

1 New “automated lifespan scanners” are designed to accelerate the discovery of compounds that slow aging. The scanners track lifespan in C. elegans—in animals that are aging naturally and in those treated with compounds that could extend their lifespan.

ABOVE This “word cloud” is composed of words appearing in the abstracts of Buck Institute studies published in 2014. The size of each word indicates its frequency of use as an indicator of importance.

4 Image of fly intestines; the nuclei are stained blue and intestinal cell structures are in green, with associated blood cells in red.

SIGNIFICANT PUBLICATIONS • Publishing in Cell, the Jasper lab provided the first systematic understanding of the aging gut microbiome, showing that altering the community of gut bacteria promotes health and increases lifespan in fruit flies. 4 • The Bredesen lab found a link between ApoE4, a major genetic risk factor for Alzheimer’s, and SirT1, an “anti-aging protein” that is targeted by resveratrol, which is found in red wine. The study was published in PNAS. • The prestigious British journal Nature published commentaries from three Buck faculty this year. In a News & Views article, “Cell biology: The beginning of the end,” Judith Campisi discussed findings suggesting that cellular senescence, which is known to suppress cancer and promote aging, may have evolved to regulate embryonic development. In “Treat Ageing; Clinical studies: Prepare for human testing,” Brian Kennedy co-authored a piece that calls for the development of biomarkers that can be used in clinical trials. Simon Melov co-authored “Treat Ageing; Preclinical studies: Track function in ageing animals,” which described methodology that would provide a bridge between interventional testing in mice and clinical trials in humans.

Buck Institute 2014 Annual Report 13

year in review THE BUCK’S GLOBAL PARTNERSHIPS Buck Institute scientists are leaders in aging research, and this is evident with their extensive research collaborations in preeminent universities, institutes, and companies situated locally, nationally, and around the globe.

SF BAY AREA Amarantus Biosciences Berkeley National Labs BioMarin CA Department of Health California Pacific Medical Center Children’s Hospital Oakland Research Institute Gladstone iRND3 Marin County Department of Health and Human Services Stanford University UC Berkeley UCSF

Brigham Women’s Hospital California Institute of Technology Cedars-Sinai Medical Center Central Michigan University Duke University Fred Hutchison Cancer Center Genomics Institute for Novartis Research Georgia Institute of Technology Harvard University Indiana University Johns Hopkins University Keck Graduate Institute Loyola University

NATIONAL

Maine Medical Center Research Institute

Albert Einstein College of Medicine

Mayo Clinic

Baylor College of Medicine

Mount Sinai Hospital

Brandeis University

Miami University

NIH

14 Buck Institute 2014 Annual Report

NYU Ogenx Therapeutics Corporation Oregon Health & Science University RestorGenex Corporation Scripps Research Institute Seahorse Bioscience Texas A&M University

University of Minnesota University of North Carolina University of North Texas University of Pennsylvania University of Pittsburgh University of Rochester

GLOBAL Akbaraly Foundation, Madagascar The Chinese University of Hong Kong Erasmus University Rotterdam, Netherlands Guangdong Medical College, China

University of Texas

The Hebrew University of Jerusalem, Israel

University of Texas Health Science Center

Institute for Medical Genetics and Human Genetics, Germany

University of Texas Southwestern

Institute of Biology Paris-Seine, France

University of Colorado

University of Washington

McGill University, Canada

University of Connecticut Health Center

Wake Forest University

Moscow Institute of Physics and Technology, Russia

UCLA UCSC UCSD University of Arkansas University of California, Irvine

University of Illinois

Washington University

University of Maine

Wayne State University

University of Maryland, Baltimore County

Worcester Polytechnic Institute

University of Miami

Yale University

University of Michigan

National Institute for Public Health and the Environment, Netherlands National University of Ireland, Galway Peking University, China

Research Institute of Molecular Pathology, Austria Seoul National University, South Korea Southern Star Research, Australia University College London, England University of Basel, Switzerland University of Chile University of Graz, Austria University of Hong Kong University of Leuven, Belgium University of Manchester, England University of Montreal, Canada University of Oxford, England Utrecht University, Netherlands

The Buck’s First Clinical Trial Is Aimed at Mild Cognitive Impairment Due to Alzheimer’s Disease

T

he Buck Institute’s first clinical trial for the treatment of mild cognitive impairment (MCI), an early indicator of Alzheimer’s disease, is under way in Australia. Emanating from groundbreaking research by Dr. Dale Bredesen and his lab at the Buck, the Phase 1b/2a trial is a randomized, double-blind, placebo-controlled study involving 36 patients.

The drug being tested, “F03,” is a therapeutic that binds three different receptors involved in cognitive function. Buck research revealed that one of those targets addresses a key process in the brain that is distorted early on in the development of Alzheimer’s disease.

Preclinical studies demonstrated that F03 improves cognitive function and alleviates memory problems in mouse models of Alzheimer’s, providing support for the drug’s disease-modifying capacity.

“It is extremely rewarding to have this work move into human trials—we are optimistic about this important first trial,” says Bredesen, whose Buck lab continues to work on Alzheimer’s therapeutics while he also takes the helm as the Director of the Mary S. Easton Center for Alzheimer’s Research at the University of California, Los Angeles.

F03 is already approved in Australia (and 48 other countries) for use in an acute indication; it is very well tolerated and appears to have a very mild side effect profile. The Phase 1b/2a trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy

of two dose levels of F03. If results (expected by the summer of 2015) are positive, F03 will advance into Phase 2a studies involving significant numbers of patients in the United States and Australia.

“We are excited to commence the first clinical trial of F03 for the treatment of MCI,” says Stelios Tzannis, PhD, the Buck’s Director for Clinical Sciences. “F03’s novel, multi-targeted mechanism of action gives us increased confidence that it may be a new, highly valuable therapeutic candidate.”

The F03 clinical trial was enabled by federal grants as well as support from the Ellen and Douglas Rosenberg Foundation, Bechtel Foundation, and Alzheimer’s Association, as well as philanthropic support from Hussam and Suhir Hasiba Abu Issa. “We are grateful for the varied sources of support that led to this groundbreaking work,” says Tzannis. “The Buck continues to build and expand its position in the field of Alzheimer’s disease and other neurodegenerative disorders, and has multiple new funding opportunities. We are poised to move the science towards development of novel, safe, and effective drugs to combat these devastating diseases.”

Stelios Tzannis (left) is running the Buck’s first clinical trial based on research by Dale Bredesen (right).

Buck Institute 2014 Annual Report 15

year in review

New Faculty Enhance the Buck’s Collaborative Environment

T

hree new faculty set up labs at the Buck this year, jumping into collaborations that showcase their research advances and support the Buck’s overarching mission to extend healthspan. Two are neuroscientists— the other is a geneticist.

PEJMUN HAGHIGHI, PHD, PROFESSOR Conventional wisdom assumes that aging leads to accumulative defects in neuronal function and signaling at synaptic junctions, followed by the loss of neural connections and degeneration. Pejmun Haghighi’s group is exploring a possibility that turns this assumption on its head.

Perhaps it’s not aging that triggers synaptic dysfunction. What if the imbalance in synaptic signaling comes first, setting off a cascade of events that leads to the “aging” of the brain manifested by age-related dementia and movement disorders?

The Buck Institute is the perfect place to continue the work Haghighi started at Montreal’s McGill University. “One of our goals is to design approaches that would address neurodegenerative diseases from a new angle,” he says. “We want to understand and hopefully reverse the imbalances in synaptic function that may precede neurodegeneration by decades.”

Haghighi is keen to understand the underpinnings of synaptic dysfunction at the molecular level and to characterize the role of disease-related genes in this process. “It’s the only way we will be able to discover the fundamental causes of neurodegenerative diseases.”

Earlier in his career, Haghighi identified the nutrient-sensing pathway target-of-rapamycin (TOR) as a critical player in balancing synaptic activity in

16 Buck Institute 2014 Annual Report

fruit flies. His focus on TOR formed an immediate connection with other Buck faculty. Collaborations with the Kapahi and Jasper labs are looking at how diet and gut function influence synaptic activity, with an emphasis on TOR as a central player. He’s also developed a model of Parkinson’s disease that the Andersen lab will use to understand how changes in synaptic function affect disease and lifespan.

JENNIFER GARRISON, PHD, ASSISTANT PROFESSOR Jennifer Garrison is a 2014 Alfred P. Sloan Research Fellow and recipient of the Glenn Foundation Award for Research in Biological Mechanisms of Aging. Her research aims to uncover the role of neuropeptides—the signaling molecules influencing processes such as appetite control, sleep, pair bonding, and energy metabolism—in aging and disease. Garrison works with C. elegans, a worm with 302 neurons, as a model to investigate the human brain with its roughly 86 billion neurons and trillions of connections. “We are still in the Dark Ages regarding the brain, the most complicated object in the universe,” she says. “This simple worm, which shares a number of neuropeptide genes and enzymatic pathways with higher animals, provides a perfect starting point for the work.”

Garrison is designing experiments with new faculty member Rachel Brem to investigate sources of genetic variation in C. elegans. She also plans to develop a strain of C. elegans that would improve early-stage drug screening. The tiny worms have a natural resistance to many foreign substances that makes them a challenge for scientists wanting to test the efficacy of drugs. Her “druggable worm” would provide a way around that.

RACHEL BREM, PHD, ASSOCIATE PROFESSOR Rachel Brem, who came from the University of California, Berkeley, is interested in how and why traits related to longevity and age-related diseases differ between individuals. These differences are due in part to changes deep within cells in the DNA sequences of genomes.

Using cutting-edge methods and computer analysis to carry out massively parallel experiments, Brem sifts through a “haystack” of genomic information from individuals within a species and looks for “needles” that impact the aging process or age-related disease. Her focus for now is on the genetics of caloric restriction, which extends lifespan and healthspan in fruit flies and single-celled yeast.

Working with Buck President and CEO Brian Kennedy and Professor Pankaj Kapahi, the Brem lab has already shown that caloric restriction has different effects on genetically distinct individuals. Mapping these genetic variations will provide new insights into aging biology and help accelerate the discovery of molecules in humans that can be targeted by new drugs.

LEFT TO RIGHT: Pejmun Haghighi, Rachel Brem, and Jennifer Garrison

Buck Institute 2014 Annual Report 17

year in review

Seed Funding from the Buck Impact Circle Rewards Researchers and Donors

BELOW Members of the Buck Impact Circle toured Buck labs in April, meeting with faculty Julie Andersen (first photo on right) and Judith Campisi (second photo in center). The group also spent time in the Patxi’s Pizza Learning Center with K–12 Education Coordinator Julie Mangada, PhD (bottom left).

T

he Buck Impact Circle is a perfect example of impact philanthropy in medical research: providing seed funding to encourage greater financial support from other sources as well as bringing donors close to the scientists they support.

The initial collaboration with the Marin Community Foundation brought $85,000 to two Buck faculty this year—Judith Campisi and Julie Andersen—enabling them to obtain preliminary data that resulted in a successful $533,000 grant application to the NIH to study environmental toxins and their potential link to senescence-related neurodegeneration in Parkinson’s disease.

Responding to an invitation from the Marin Community Foundation, the Institute developed the Buck Impact Circle as an opportunity for Marin residents to become more intimately engaged with the work being done at the Buck and to tap into deep regional interest in matters relating to healthy aging.

A group of 19 donors pooled their individual contributions to create the first Impact Circle, and subsequently indicated their strong support for one of the eight scientific research projects that were presented to the group.

Buck Impact Circle members and staff from the Marin Community Foundation attend the Buck Advisory Council dinner. From left: Andrew and Ann Matheison, Dorene Schiro, Brian Van Weele and Linda Sweeney of Marin Community Foundation, and Dayton Coles.

The Buck Impact Circle gave their inaugural award to Campisi and Andersen for work on “Cancer and the Aging Brain.” Campisi is internationally recognized for her pioneering work on senescence, a tumor suppressor mechanism that also drives aging. Andersen, who brings her expertise in neurodegeneration to studies involving the aging brain, has received awards for her research on Parkinson’s disease. This collaborative approach to aging research from scientists in disparate fields is unique to the Institute and was highly attractive to donors.

Members of the Buck Impact Circle visited both the Andersen and Campisi labs, where they met the bench scientists who are doing the experiments. “It is extremely exciting and gratifying to have a front row seat to the research being done at the Institute,” says Impact Circle member Dayton Coles. “As a Marin resident, I now have a way to support an internationally recognized organization, located in my own backyard, that is changing the way the world ages. Getting to have a personal relationship with the scientists is a huge thrill.”

“I am so happy to get to know the people who are supporting our research,” Andersen says. “Scientists love what they do, and to be able to share our enthusiasm and gratitude directly with donors is hugely satisfying and motivating.”

Given the success of the inaugural program for both scientists and donors, Carlotta Duncan, PhD, the Institute’s Director for Scientific Advancement, is now looking to expand this initiative to include more donors who will be able to have an impact on multiple Buck projects and disease areas.

18 Buck Institute 2014 Annual Report

Historic BAIT Project Opens New Path from Animal Studies to Human Trials

A

case can be made that BAIT—the Buck Aging Intervention Testing project—is the most significant scientific venture undertaken in the Institute’s history. Designed to provide a needed roadmap for moving promising therapies from mice into humans, BAIT has received kudos from national officials and is energizing Buck scientists who are eager to move the research forward.

BAIT is the largest study on aging in mice involving drug interventions that could extend healthspan.

Going beyond survival data, it is one of the first studies to track function both in mice that age naturally and those treated with drug interventions.

Function, says project director Simon Melov, is where the scientific “gold” needs to be mined. “Once we determine how interventions impact cardiac tissue, bone, metabolism, and other systems in mice, we’ll be able to make exciting connections to similar measures in humans,” he says. “That’s the only way we’re going to be able to design human clinical trials to test the compounds that work, and we need that common ground.”

“Pharmaceutical companies don’t know what to do when I tell them we can make mice live longer,” says Buck CEO Brian Kennedy, who facilitated the project by committing institutional funds to it. “When I talk about measuring age-related cardiac hypertrophy or bone density, they get excited—there are markets for those

CT scan of a live mouse showing the skeleton.

The colored bones represent areas of interest in regards to age-related changes in bone.

conditions,” he says. “BAIT gives us a way to meet drug developers half way, and it also connects us with human researchers and gerontologists in the clinic.”

The first phase of BAIT, initiated in January 2013, involved 4 compounds and 770 genetically identical mice that entered the study at 20 months of age (roughly equivalent to a 60-year-old human). The research yielded terabytes of data that are being analyzed by scientists from five labs. In the meantime, fundraising for the second phase of BAIT is under way—an effort that could involve as many as 1,500 mice and 20 new drug interventions.

“In the past decade, clinical testing standards for humans have been developed that involve balance, memory, muscle strength, walking speed, blood pressure, and bone density, among others,” says Kennedy. “By adapting and testing those assessments in the mice, BAIT will help us determine which interventions should be advanced to human testing.”

Kennedy says this is where it gets really exciting. “There are numerous pharmacological compounds and nutritional interventions that show promise in animal models, but we’ve not been able to move them forward into human clinical trials. BAIT gives us a way to cross that chasm.”

LEFT Emmeline Academia, a research associate in the Kennedy lab, checks fittings on cages that measure multiple metabolic metrics in mice.

Buck Institute 2014 Annual Report 19

year in review

Buck Scientists Collaborate with Amarantus to Develop a Protein That Prevents Cell Death Amarantus Bioscience is sponsoring research in both the Jasper and Lamba labs, engaging their postdoctoral fellow Joana Neves, PhD. Neves showed that the secreted protein MANF (mesencephalic astrocyte-derived neurotrophic factor) may be a critical factor in retinal tissue repair in flies and mice.

MANF is a proprietary protein held by Amarantus, a company focused on discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death). MANF is a targeted therapeutic that addresses the underlying pathology associated with a wide range of devastating human disorders, including retinitis pigmentosa and Parkinson’s disease.

“We were highly impressed with preliminary data generated at the Buck Institute,” says Gerald E. Commissiong, president and CEO of Amarantus.

“Given the stellar science from the Jasper and Lamba labs, we are confident that this will be just the beginning of our relationship with the Buck.”

LEFT Postdoc Joana Neves spearheads a sponsored research project involving the secreted protein MANF, which is upregulated in response to retinal damage in both the fly and the mouse.

Buck Hosts Kazakh Scientists Five scientists on fellowships from Kazakhstan came to the Buck for training on cutting-edge stem cell and genomic technology. Buck faculty Victoria Lunyak (center) mentored their investigation of treatments for skin wounds in diabetic patients.

Three will continue their work in the new Kazakh Genomic Facility at Asfendiyarov Kazakh National Medical University. Two remain on year-long fellowships at the Buck in the Lunyak and Benz labs.

Brian Kennedy is at top left.

20 Buck Institute 2014 Annual Report

Buck Advisory Council Members Invest in Buck Science Through their Weldon Foundation, Inc., father-and-son team Norm (below, right ) and Tom Weldon (below, left ) are funding research in the Kennedy, Lithgow, and Pankaj Kapahi (below, center) labs. Their $200,000 investment allows scientists to study the impact of natural products on aging in yeast, worms, and fruit flies.

Hussam Abu Issa is supporting epilepsy research in the lab of Lisa Ellerby. The research is based on findings that show possible shared mechanisms between epilepsy and Huntington’s disease. This year he gave more than $169,000 to purchase needed technology and to support scientists studying the effects of epilepsy drugs in mouse models of the disease.

Through his company Ivivi Health Sciences, LLC, Steven M. Gluckstern (on right with Pejmun Haghighi ) sponsored $35,000 in research for the Haghighi lab to measure the impact of pulsed electromagnetic field exposure on synaptic transmission in fruit flies.

LabCures LabCures, a new Buck for-profit spinoff, hopes to generate money for life sciences research by using the Internet to attract lots of small donations. Different from typical crowd-funding sites, LabCures will only feature research from established labs, and donations will go immediately to researchers without having to meet a threshold for initial funding before donations are collected.

Buck Institute 2014 Annual Report 21

year in review

Busy Year in the Patxi’s Pizza Learning Center Foretells Major Program Expansion The Buck Institute’s K–12 education program touched more than 2,200 children in 2014—a number that is poised to swell, thanks to a major gift from Bill Freeman, the CEO of Patxi’s Pizza and a Buck Advisory Council member.

Known for local philanthropy dedicated to education and children’s health and welfare, Patxi’s is working with the Buck Institute to develop

22 Buck Institute 2014 Annual Report

special summer camps and scholarship programs to reach underserved children who would not generally have opportunities to be immersed in science. Plans are also being made for additional science education outreach through Patxi’s res­ tau­rants, with nine locations in the Bay Area and stores in Denver and Seattle.

“The Buck is a perfect partner for us,” says Freeman. “Working toward a healthy lifespan for the children of today is a great way to ensure the world’s future. We’re very excited about the programming and opportunities the Patxi’s Pizza Learning Center will offer the Bay Area community and beyond.”

Buck Advisory Council member Bill Freeman with the 2014 Summer Scholars in the Patxi’s Pizza Learning Center.

Buck Institute 2014 Annual Report 23

year in review

The Buck Institute and the University of Southern California Launch PhD Program in the Biology of Aging

F

or the first time in this country, a program is under way to train PhDs who will be experts in the biology of aging, thanks to the vision and collaborative intent of leaders at the Buck Institute and the University of Southern California (USC) Davis School of Gerontology.

Four students have been selected for the 2014 inaugural class, which will feature course work and bench-based research at both campuses. The joint Buck-USC program will include research and education on regenerative medicine and the molecular, cellular, and integrative biology of aging.

“Establishing this PhD program marks a milestone in the development of the Buck, both in terms of our mission and our commitment to lead the field of aging research,” says Buck president and CEO Brian Kennedy. “The next generation of scientists dedicated to extending human healthspan are waiting in the wings—this program will allow them to jump into the field fully prepared to participate and make their own breakthroughs.”

Most of the students selected for the program already have a firm footing in aging research. Megumi Mori comes from Montreal’s McGill University, where she worked on age-related neurodegeneration in fruit flies (Drosophila)

LEFT from top: Azar Asadi Shahmirzadi, Megumi Mori, and Maria Konovalenko RIGHT Kenneth Wilson

24 Buck Institute 2014 Annual Report

under the tutelage of Buck faculty Pejmun Haghighi, who maintains a lab there. Maria Konovalenko will arrive from Moscow with a master’s degree in applied mathematics and physics and extensive knowledge of aging research, acquired as vice president of Science for Life Extension, a nonprofit foundation aimed at supporting and increasing funding for the field. Azar Asadi Shahmirzadi received a Doctor of Pharmacy degree from Tehran University of Medical Sciences, where she focused on irritable bowel syndrome.

Kenneth Wilson begins his PhD studies already knowing his way around the Buck. A Novato native, he received his master’s degree from Dominican University, working under Buck faculty Pankaj Kapahi, who urged him to apply for the program. After initial coursework at USC, he will be back in the Kapahi lab, managing 180 strains of fruit flies on various diets and looking at natural genetic variations that extend lifespan and impact metabolism, body weight, and activity levels.

Celebrating Our History

From Dream to Reality—1975 to 1999 back. In March of 1985, Marin County Supervisor Gary Giacomini proposed resolving the dispute by using half of the estate to create a new research center in Marin that focused on Alzheimer’s and age-related diseases. That same month, in response to the trial judge’s call for settlement options, Mrs. Buck’s executor, John Elliot Cook, proposed the creation of a freestanding research institute on aging in Marin County.

In preparing the case for trial, Mr. Cook’s attorney, Mary McEachron (now the Buck Institute’s Chief Administrative Officer), asked eminent gerontologist John W. Rowe, MD, of Harvard Medical School to convene a panel of renowned experts in aging to consider the feasibility of creating such a research center. The seven-member panel created a vision and a preliminary plan for a collaborative institute of distinguished scientists from diverse fields—all focused on research with the greatest potential to extend the healthy years of life.

The history of the Buck Institute begins with Beryl Hamilton Buck. In letters to her trustees, she said that, among other things, she wanted “to extend help toward the problems of the aged,” not only the indigent, but those afflicted by accident and illness late in life.”

“We can only imagine how proud Auntie Beryl would be of the incredible gift she sponsored to improve the quality of life for those who are challenged with the aging process” —Bill and Vicki Hamilton, Beryl Buck’s grand-nephew and his wife The Marin philanthropist died in 1975. The events that led to the opening of the Buck Institute in 1999 followed one of the most highly publicized and studied chapters in American philanthropy.

Mrs. Buck left most of her estate (initially valued at $10 to $12 million) to The San Francisco Foundation, to be spent in Marin County. By the time probate settled in 1979, the value of the Buck estate had swelled to $262 million, thanks to the sale of Belridge Oil, a closely held corporation that owned the nation’s largest private oil reserves.

In 1984, The San Francisco Foundation filed suit to break the Marin-only restriction of Mrs. Buck’s trust. As expected, Marin County officials fought

After a six-month trial, litigation settled. The Marin Community Foundation was appointed successor trustee to The San Francisco Foundation, and a decision was made to select three “Major Projects” to share 20 percent of the annual income from the Buck Trust. At the request of Mr. Cook, and with the approval of Beryl Buck’s family, the “Buck Institute on Aging” was incorporated in November 1986.

For nearly a year, McEachron worked to rally public support for the selection of the Buck Institute as one of the Major Projects. In August 1987, with the backing of many community and governmental organizations and thousands of individuals, the Marin Superior Court selected the Institute to receive 15 percent of the net income from the Buck Trust in perpetuity.

Two years later, the Buck purchased its current 488-acre site on Mount Burdell in Novato, and internationally acclaimed architect I.M. Pei was selected to design the facilities. Despite strong efforts by opponents of animal research to stop the project, construction began in 1996 and the Institute formally opened in September 1999, with Dale Bredesen, MD, as its founding president.

The Buck Institute became the first research center in the nation to fulfill the challenge of a 1991 National Academy of Sciences report calling for the establishment of at least 10 centers of excellence focused on research on aging.

Buck Institute 2014 Annual Report 25

Celebrating Our History

Q & A with Dr. John W. Rowe on the Founding of the Buck

ABOVE Dr. John W. Rowe, who led the panel of experts that helped create the Buck Institute LEFT An early meeting of the Buck Institute’s first Scientific Advisory Board

I

n 1985, John W. Rowe, MD, assembled a panel of experts to consider the creation of the Buck Institute, and he later testified as an expert witness at the trial that led to its inception. Dr. Rowe, then the founding director of the Division on Aging at Harvard’s Medical School, also served as a Buck Trustee and the head of our Scientific Advisory Board.

Retired as chairman and CEO of Aetna, Inc., he is now a professor in the Department of Health Policy and Management at the Columbia University Mailman School of Public Health.

Can you put the development of the Buck Institute in context?

In 1985, when the opportunity arose to develop an institution that was research-based and focused

26 Buck Institute 2014 Annual Report

solely on issues of aging, there was increasing awareness of the demographic transformation in this country, but most of the efforts focused on services for older people. The National Institute on Aging had been founded, but it was just beginning to find its way.

Describe the actual meeting of the group later known as “The Chicago Panel.”

We assembled a group of scholars who were highly respected in various domains that were relevant to age-related research. We tried to find a convenient place to meet, so we wound up in terrible conference rooms in the basement of a hotel in the middle of O’Hare Field in Chicago. But the good thing

“For me to see where we are now very much reminds me of a piece from Aristotle. Aristotle taught us the difference between potentiality and actuality. In those days, we were dealing with potentiality. Today, we’re sitting here in the —John W. Rowe, MD midst of actuality.”

LEFT The development team visits the future site of the Buck Institute in 1990.

Mary McEachron (front, third from left) stands next to architect I.M. Pei. BELOW Campaign button from 1995.

Voters in Novato approved “Measure B,” which cleared the way for the Buck Institute to be built on Mt. Burdell.

about it was there were no distractions from the conversation—no windows, nothing else to go see or do.

Led by Mary McEachron, who had a vision for how this might be accomplished from the legal, financial, organizational, and community points of view, we tried to fill in the white space on the canvas that dealt with issues related to the science and education as well. That was a very exciting meeting for me, and I think for the others who participated.

We came up with a strategy, and we came out with enthusiasm.

The meeting dealt with scientific strategy, the establishment of a Board of Trustees and a Scientific Advisory Board, executive leadership, and faculty recruitment. What was your over­ arching goal at that time?

We saw the opportunity to send a signal, to establish a freestanding, independent, high-quality research center that was interdisciplinary and included different kinds of scholars working together, but at the same time, focused on issues solely related to aging. We saw this as the first such

institute in the United States, one that would be a model for the kinds of research that could be done and for the kinds of people who could be trained.

It’s our 15th anniversary. How have we done?

The Buck is very much recognized in the field of biogerontology—it has had a dominant role in fueling the interdisciplinary activities that are now a feature of the field.

I think the focus of the Buck—the intense focus on these issues—provides supporters with leverage.

It’s like a laser. And there’s not a lot of the stuff that goes on in large universities. There’s not a lot of administration soaking up the money, not a lot of bureaucratic barriers. The Buck is able to get the work done and get it done in a specific, interdisciplinary, nimble way.

The Buck has also successfully demonstrated an ability to retain key scientists over time. Churn is very counterproductive and expensive. And you want to maintain your momentum in those laboratories and keep them efficient. You want to keep those leading scientists around, and the Buck has been able to do that.

Buck Institute 2014 Annual Report 27

2014 board of trustees The Buck Institute receives support and guidance from a non-compensated Board of Trustees.

These recognized leaders from the business, science, and nonprofit communities set policy, approve financial plans, and help shape the strategic direction of the Institute.

Richard “Dick” Bodman

Jim Gerber

Fouad Makhzoumi

E. Lewis Reid

Chairman of PurThread Technologies, Inc.

Co-founder of Western Athletic Clubs, Inc., the owner and operator of luxury athletic and health facilities throughout the West Coast

Executive CEO of Future Group, including Future Pipe Industries Group of Dubai, which has over 3,500 employees in 23 countries

Former Chair of Buck Board of Trustees

Stephen Hauser, MD

Former member of the International Board of the Council on Foreign Relations: US/Middle East Project

Chairman of Layalina Productions, Inc. Managing General Partner of VMS Group General Manager of Bodman Oil & Gas, LLC

Nathaniel “Ned” Eames David, PhD Partner, Arch Venture Partners

James Edgar

Chair, Department of Neurology, UC San Francisco Chair, Buck Institute Scientific Advisory Board

Harlan P. Kleiman Co-founder and CEO of Self Health Network

Founder of the Makhzoumi Foundation, which helps increase the standard of living for underprivileged Lebanese

Barbara Morrison Vice-Chair of the Buck Advisory Council

Management consultant

Founder/CEO of Shoreline Pacific

Founding member of Edgar, Dunn and Company, an international consulting firm

Co-founder of Long Wharf Theatre UCLA School of Theater, Film and Television Board Member

Roy Eisenhardt

Charles La Follette

Bay Area civic and business leader

President of La Follette Capital

Former President of the Oakland A’s baseball team

Founder and Board President of Working Solutions, a nonprofit that helps micro-entrepreneurs access capital

Edward Lanphier Founder, President, CEO, and member, Board of Directors of Sangamo BioSciences, Inc.

David M. Perry

Former Executive Director of the California Academy of Sciences Currently serves as a Trustee of the California Pacific Medical Center Foundation Frequent interviewer at City Arts & Lectures

John W. Larson

Chairman and Founder of Bay West Group in San Francisco

Shahab Fatheazam

Former Chair of the San Francisco Chamber of Commerce and President of the Branson School

M. Arthur Gensler Jr., FAIA Founder of Gensler, a global architecture, design, planning, and strategic consulting firm

Senior Managing Director of TeamCo Advisers

Bill R. Poland

Retired San Francisco lawyer with over 40 years of practice devoted to high-tech and life science companies

Managing Director and head of Healthcare Group, Lincoln International

Mayor of Belvedere, CA

Board member of Biotechnology Institute

Lecturer in law at the University of California, Berkeley

Chairman, Buck Advisory Council

President of TMC Development, a provider of real estate financing

Current Chairman of WageWorks, a NYSE company

Fay Hartog Levin Former U.S. Ambassador, the Netherlands

28 Buck Institute 2014 Annual Report

Real estate developer

Franklyn Prendergast, MD, PhD Professor of Biochemistry and Molecular Biology and Professor of Pharmacology and Experimental Therapeutics at the College of Medicine at the Mayo Clinic in Rochester, Minnesota Director Emeritus of the Mayo Clinic Comprehensive Cancer Center and of the Mayo Clinic Center for Individualized Medicine Emeritus member of the Mayo Clinic Board of Trustees

Director of Community Foundation Sonoma County

Larry E. Rosenberger Former President and CEO and current Research Fellow of Fair Isaac Co-author of The Deciding Factor: The Power of Analytics to Make Every Decision a Winner

Ralph Snyderman, MD Chancellor Emeritus at Duke University and James B. Duke Professor of Medicine Former Chancellor for Health Affairs and Dean of the School of Medicine at Duke Vice President for Medical Research and Development at Genentech Member of the Institute of Medicine and the American Academy of Arts & Sciences

Charles M. Stockholm Semi-retired business executive with over 50 years of commercial financial experience, primarily in the AsiaPacific region Served as Chairman of Citibank International and was Senior Executive Vice President of Crocker National Bank President of the Bay Area Council of the Boy Scouts of America President of the Asian Art Museum Foundation of San Francisco

scientific advisory board The Scientific Advisory Board (SAB) consists of leading scientists in the fields of aging research and age-related diseases, such as Alzheimer’s disease and cancer. Members of the SAB provide guidance on the Institute’s scientific and educational programs.

Stephen L. Hauser, MD Chair, Buck Institute SAB Chair, Department of Neurology, UCSF

Robert H. Brown Jr., MD, DPhil Professor and Chairman, Department of Neurology, University of Massachusetts Medical School

Steven A. Carr, PhD Director of Proteomics, Broad Institute of MIT and Harvard

Ana Maria Cuervo, MD, PhD Department of Developmental and Molecular Biology, Marion Bessin Liver Research Center, Albert Einstein College of Medicine

In Memory of Catherine Munson January 21, 1928 – March 3, 2014 Catherine Munson was a longtime Buck Institute Board Trustee and former Board Chair. Her ambassadorship and philanthropic generosity inspired many to support the Institute’s mission to extend the healthy years of life through research and education.

She has left a lasting mark on the Institute. Her friendship will be sorely missed.

The Buck celebrates her remarkable life and congratulates her on being an example of healthy aging.

Catherine was 86 years old, in good health and fully engaged in life prior to succumbing to a brief, serious illness.

Cynthia J. Kenyon, PhD Vice President, Aging Research, Calico

James L. Kirkland, MD, PhD Professor of Aging Research, Director of Mayo Clinic Robert and Arlene Kogod Center on Aging

Jeffrey D. Macklis, MD, DHST Director, MGH-HMS Center for Nervous System Repair, Harvard University

Thomas A. Rando, MD, PhD Director, Glenn Laboratories for the Biology of Aging; Professor of Neurology and Neurological Sciences, Stanford University School of Medicine Deputy Director, Stanford Center on Longevity, Stanford University

Buck Institute 2014 Annual Report 29

buck advisory council The Buck Advisory Council (BAC) is a global network of diverse individuals who advocate for the Buck Institute and its mission—to increase healthspan through research and education. The BAC includes leaders in government, business, finance, pharmaceuticals, law, philanthropy, and other fields. Many have served as advisors to governments, universities, public commissions, and nonprofit organizations.

Dorothea Dutton

William Freeman

Vice President, Wealth Management Consultant, The Private Client Reserve of U.S. Bank

Founder and CEO, Patxi’s Pizza

San Francisco, CA

Shafik Gabr

BAC members advise the Buck on strategic priorities, serve as informal ambassadors to raise awareness of our achievements, and set the pace for philanthropy at the Institute.

David Elias Principal, Alesco Advisors

Chairman, Managing Director, ARTOC Group for Investment and Development

East Amherst, NY

Cairo, Egypt

Peter G. Ellis

Steven M. Gluckstern

Principal, Cannon Design

Chairman, Ivivi Health Sciences LLC

Arthur Ablin

Shadi Arnita

Deepak Chopra

Professor Emeritus, Clinical Pediatrics, UCSF

Founder and Chairman of the Board, A&Z Pharmaceutical, LLC

Founder and CEO, Eckhart Corporation

San Francisco, CA

Hussam Abu Issa Vice-Chairman and COO, Salam International Qatar

Tarek AbuZayyad

Pittsburgh, PA

Mikhail Batin Executive Director, Science for Life Extension Foundation Moscow, Russia

Partner, Head of Merchant Banking, Stanhope Capital LLP

Peter Bennett

London, UK

San Francisco, CA

Cinzia Akbaraly

Jeff Bohnson

Founder and Member, Akbaraly Foundation Honorary General Counsel of Italy in Madagascar Groupe SIPROMAD

CEO and Founder, Best In Class Care

Madagascar

Chester P. Aldridge Chairman and CEO, US Equity Holdings Greenbrae, CA

James A. Aleveras J.P. Morgan Securities LLC San Francisco, CA

The Honorable George Antoun General Honorary Consul, Consulate of Kyrgyzstan Lebanon

Wissam Ariss Founder and Chairman of the Board, Star Goods Lebanon

Managing Director, Greenhill Global, LLC

Chicago, IL

Razmig Boladian Founder, Rubicon Point Partners San Francisco, CA

Patricia L. Cahill Kentfield, CA

Najib Canaan

Chicago, IL

Novato, CA

Shannon Fairbanks

Louis Ciminelli

Founder & Chairman, The Fairbanks Investment Fund

Chairman and CEO, LPCiminelli

Washington, D.C.

Buffalo, NY

San Francisco, CA

San Francisco, CA

Catherine T. “Kiki” Goshay Founder, Kiki Goshay Productions Kentfield, CA

Dayton Coles Larkspur, CA

Sheri Coles Larkspur, CA

A. Crawford Cooley Novato, CA

Sherri Corker San Rafael, CA

Mark Cutis Chief Investment Officer, Abu Dhabi Investment Council United Arab Emirates

The BAC awarded its 2014 Global Humanitarian Award to May Makhzoumi, President of the Makhzoumi Foundation. The Foundation, headquartered in Beirut, was the first organization in Lebanon to partner with the UN Refugee Agency to provide relief to those fleeing Syria.

Mazen Darwazeh Executive Group Vice-Chairman, Hikma Pharmaceuticals PLC

Shahab Fatheazam

Stephen A. Goveia

Founder, Marinus Capital Advisors, LLC

Pleasanton, CA

Darien, CT

Jordan

Chairman, Buck Advisory Council

Margaret E. Haas

Daniel E. Cantara

Larry D. Dingus

Trustee, Buck Institute for Research on Aging

Buffalo, NY

San Anselmo, CA

Managing Director and Head of the Healthcare Group, Lincoln International LLC

Mehmet Celebi

Kevin Dorwin

Chicago, IL

Founding Partner, Investments, Construction, Arti Bir Group

Managing Principal, Bingham, Osborn & Scarborough LLC

Darla Flanagan

Madrid, Spain

San Francisco, CA

30 Buck Institute 2014 Annual Report

Ross, CA

James W. Harpel Senior Partner, Palm Beach Capital West Palm Beach, FL

General Partner, MKD Investments

Maher Kaddoura

San Francisco, CA

Jordan

Social Entrepreneur

Buck Advisory Council Nilesh Satish Kanade CEO, NCORD Biotech Ltd. Pune, India

Dato Fawziah Abdul Karim CEO, SSU Management Services Malaysia

Lady Jamileh Kharrazi Chairman, Jamileh Kharrazi Charitable Foundation United Kingdom

Arthur Kirsch Senior Advisor, GCA Savvian New York, NY

Harlan P. Kleiman Trustee, Buck Institute for Research on Aging CEO, Self Health Network San Francisco, CA

Ronald G. Landes President, SOS Solving Organ Shortage Austin, TX

Edward Lanphier Trustee, Buck Institute for Research on Aging Founder, President, CEO, and member, Board of Directors of Sangamo BioSciences, Inc.

Buck Advisory Council members at the 2014 spring meeting, which was held on the Buck campus Peter J. Marguglio

Veena Panjabi

Larry E. Rosenberger

Neill Walsdorf Sr.

Tiburon, CA

Vice President and Co-owner, World Industries

Chair of the Buck Institute Board of Trustees

CEO, Mission Pharmacal Company

Joseph Maroun Sr.

Miami, FL

Noel Thomas Patton

Former President and CEO and current Research Fellow of Fair Isaac

San Antonio, TX

Chairman of the Board, Harissa LLC and Azour LLC Menlo Park, CA

Founder, T.A. Sciences

San Quentin, CA

President, Mission Pharmacal Company

Susan E. Mayer

New York, NY

Professor, Harris School of Public Policy, University of Chicago

Kevin Perrott

Chicago, IL

Mountain View, CA

Maura B. Morey Tiburon, CA

Barbara Morrison Vice-Chair of the Buck Advisory Council

Director, SENS Research Foundation

Kaveh Safavi Managing Director, Global Health Care, Accenture

Marika Sakellariou

Judy C. Webb

Dan Perry

Luxury Home Specialist

Belvedere, CA

President, Alliance for Aging Research

Corte Madera, CA

Washington, D.C.

Rubar S. Sandi

Ross, CA

Washington, D.C.

President, TMC Development

Bruce Raabe

Rashid M. Skaf

Jessica Lewin

San Francisco, CA

CEO, S. R. Travel

President and CEO, AMX Corporation

Cherilyn Murer

Founder and President, Relevant Wealth Advisors

San Francisco, CA

San Francisco, CA

William N. Macartney III Clinton, NY and Naples, FL

Fouad Makhzoumi Trustee, Buck Institute for Research on Aging Executive Chairman and CEO, Future Pipe Industries Lebanon

President and CEO, Murer Consultants, Inc. Joliet, IL

Bora Ozturk Founder and General Partner, March Capital Management San Francisco, CA

Robert J. Palay Chairman & CEO, Cellular Dynamics International Madison, WI

Marylin P. Wanlass Santa Rosa, CA

Mary Poland

Trustee, Buck Institute for Research on Aging

San Antonio, TX

Chicago, IL

Chairman, CEO, TSG Global Holdings

Board member of Biotechnology Institute

Neill Walsdorf Jr.

Mill Valley, CA

Richardson, TX

E. Lewis Reid

Richard Stone

Trustee, Buck Institute for Research on Aging

Founder and Chairman, Private Ocean

Sebastopol, CA

San Rafael, CA

Chris Reiter

Linda K. Trocki

Senior Vice President, Partner, Woodruff-Sawyer

Tiburon, CA

Novato, CA

Brooke N. Wade

Douglas Rosenberg

President, Wade Capital Corporation

Kentfield, CA

Vancouver, Canada

Norman R. Weldon Amelia Island, FL and Evergreen, CO

Thomas D. Weldon Chairman, Managing Director, Accuitive Medical Ventures Amelia Island, FL

E. Packer Wilbur Chairman, Southport Properties Southport, CT

Donald F. “Fritz” Zimmer Jr. Partner, King & Spalding, Tort and Environmental Litigation Group San Francisco, CA

Buck Institute 2014 Annual Report 31

financial summary Operating and Capital Revenue for FY2014 Corporate Research Agreements 5.3%

Contributions 12.2% Interest and Other 4.0%

Foundation and Other Grants 9.8% Buck Trust 17.5%

Government Grants 51.2%

cumulative donors

M

any extraordinary individuals and institutions have been inspired by the Buck’s interdisciplinary research on aging to make financial contributions to ensure that the Institute thrives and the research continues. Among this group are some who have given generously over many years to a variety of programs and initiatives— highlighting their commitment to the growth and stability of the organization while demonstrating their belief in the Buck’s mission, its exceptional scientists, and the remarkable research undertaken here. We are extremely proud and fortunate to have been the recipient of such steadfast support.

$5,000,000 and above Drucilla and Arthur Gensler Ellen and Douglas Rosenberg

Operating Expenses for FY2014 Fundraising 4.1%

Bond Interest and Related Costs 5.4%

$2,500,000–$4,999,999 Fred Drexler Marylin P. Wanlass

$1,000,000–$2,499,999 John W. Bissinger, Jr. Trust General and Administrative 21.6%

Phyllis M. Faber Judy and James Harpel William G. Irwin Charity Foundation JEC Foundation Nichola Jo and Craig Johnson La Follette Family Fund Cameron and Edward Lanphier Elisabeth R. Levy Mary and Lew Reid Barbara C. and Richard M. Rosenberg Elizabeth M. Stevens

Mericos Foundation Research 68.9%

Rowe Family Foundation

$50,000–$99,999

Wayne and Gladys Valley Foundation

Zarife and George Antoun

$500,000–$999,999 Anonymous Barbara and Gerson Bakar Jess and A. Crawford Cooley

Marjorie E. Belknap Buck Institute Impact Circle Fund Kelli and G. Steven Burrill Ann and Louis Ciminelli Joey and Warren C. Conklin

William T. and Kathryn Freeman

Joan Corrigan

Harold J. and Reta Haynes Family Foundation

Mark N. Cutis Sandra D. Donnell

Michaela and Jay Hoag

Linnea and Jim Gerber

100%

Catherine H. Munson

Margaret E. Haas Fund

90%

Mary and Bill Poland

Brenda and Brian Kennedy

Diane and Larry Rosenberger

Lady Jamileh Kharrazi

Percent of Total Budget Funded by the Buck Trust (FY1999–2014)

80%

Pamela and John Larson

70% 60% 50%

$100,000–$499,999

Fay Hartog-Levin and Daniel E. Levin

Suhir and Hussam Abu Issa

May and Fouad Makhzoumi

Cinzia and Ylias Akbaraly

40%

Myfanwy Ozeroff and James Aleveras

30%

Aida and Dale E. Bredesen

20%

Corinne Hellier Buck 1993 Trust

10%

Patricia L. and John Cahill, Jr. 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

Mary C. Sauer and Robert J. Doris

32 Buck Institute 2014 Annual Report

Judy and James Edgar

Mary McEachron Rita and Herbert Myers Susan Ohrenschall Herbert Simon Family Foundation Judy C. Webb

cumulative sponsors $10,000,000 and above The Buck Trust California Institute for Regenerative Medicine National Institutes of Health

$5,000,000–$9,999,999 CHDI Foundation The Ellison Medical Foundation

$2,500,000–$4,999,999 The S. D. Bechtel, Jr. Foundation Larry L. Hillblom Foundation

California Breast Cancer Research Program

Foundation for Retinal Research

eBioscience

Glenn Foundation for Medical Research

Michael J. Fox Foundation William Randolph Hearst Foundation

John Douglas French Alzheimer’s Foundation

W.M. Keck Foundation Neurobiological Technologies U.S. Department of Defense

$500,000–$999,999

The Hereditary Disease Foundation William G. Irwin Charity Foundation Johnson & Johnson

BioMarin Pharmaceuticals Joseph Drown Foundation

U.S. Department of Energy

Seahorse Bioscience Simon-Strauss Foundation Wings of Freedom Foundation

Wells Fargo

Institute for the Study of Aging

$50,000–$99,999 $100,000–$499,999

Alva LLC American-Italian Cancer Foundation

Anonymous

American Parkinson Disease Association

American Biosciences

The Brookdale Foundation

American Federation for Aging Research

Cenexys, Inc.

$1,000,000–$2,499,999

Oracle Corporation Progeria Research Foundation

Mitokor National Parkinson Foundation

Alzheimer’s Association

Huntington’s Disease Society of America PEW Latin American Fellows Program

Merck & Co. Muscular Dystrophy Association

Anonymous

Hereditary Disease Society of America

Danish Cancer Foundation Electrophoretics Limited

Avon Foundation Breast Cancer Crusade Breast Cancer Research Program The California Endowment Winifred Johnson Clive Foundation

honor roll of donors The following gifts were received between July 1, 2013, and June 30, 2014.

Michael and Catherine Podell Fund

Nathaniel E. David

Jessica Lewin

William T. and Kathryn Freeman

Mary and Bill Poland

Gunnel and Larry Dingus Kevin Dorwin

William N. and Linda Macartney

$250,000–$499,999

Cameron and Edward Lanphier

Emine and Rubar Sandi

Suhir and Hussam Abu Issa

Pamela and John Larson

$500,000 and above John W. Bissinger, Jr. Trust Drucilla and Arthur Gensler

$100,000–$249,999 Barbara and Gerson Bakar Harold J. and Reta Haynes Family Foundation Nichola Jo and Craig Johnson Diane and Larry Rosenberger

Ann and Louis Ciminelli Joan Corrigan

May and Fouad Makhzoumi Catherine H. Munson Barbara and Richard Rosenberg

$25,000–$49,999 Myfanwy Ozeroff and James Aleveras

Mary and Lew Reid

$10,000–$24,999 Frank Howard Allen & Co. Elizabeth and Shadi Arnita Karna and Richard Bodman Ani Vartanian and Razmig Boladian The William Boone Educational Foundation, Inc.

Judy and James Edgar Barbara and David Elias Peter G. Ellis and Paula Garrett-Ellis Neghmeh and Shahab Fatheazam Darla and Patrick Flanagan Selim J. Ghorayeb Judy and Steven Gluckstern Kiki Goshay Margaret E. Haas Fund Maher Hikmat Mahmoud Kaddoura

Zarife and George Antoun

Corinne Hellier Buck 1993 Trust

Mark N. Cutis

Lynn and Najib Canaan

Betsy and Roy Eisenhardt

Lori and Daniel Cantara

Dato Fawziah Abdul Karim

Cinzia and Ylias Akbaraly

Linnea and Jim Gerber

Brenda and Brian Kennedy

Buck Institute Impact Circle Fund

Judy and James Harpel

Deepak Chopra and Deep Mala

Lady Jamileh Kharrazi

Kelli and G. Steven Burrill

Fay Hartog-Levin and Daniel E. Levin

Jess and A. Crawford Cooley

Arthur Kirsch

Sherri Corker

Patricia and Jay Cahill

Sandy and Harlan Kleiman

Elisabeth R. Levy

Rula and Mazen Darwazeh

La Follette Family Fund

Marylin P. Wanlass

$50,000–$99,999

Rupa and Nilesh Kanade

The Florence S. Mahoney Foundation Linda Trocki and Peter Marguglio Carmen and Joseph Maroun Sr. Tad Mitchell Barbara H. Morrison Cherilyn and Michael Murer Noel Thomas Patton Carol and Daniel Perry Laura and David Perry Chris Reiter Kaveh T. Safavi Marika Sakellariou Rashid Skaf Elizabeth M. Stevens Maryanna and Charles Stockholm Richard Stone

Buck Institute 2014 Annual Report 33

honor roll of donors Tracy and Brooke Wade Beverly and Neill Walsdorf Sr. Neill B. Walsdorf Jr. Norman R. Weldon Thomas D. Weldon

$5,000–$9,999 Deborah and Arthur Ablin Family Fund Wissam Issam and Yasmine Ariss Marjorie E. Belknap Margery and Rick Blume Aida and Dale Bredesen Jane and David Duncan Dorothea M. Dutton Phyllis M. Faber Linda and Stephen Goveia Marin Financial Advisors, LLC Jolson Family Foundation Raja Kamal and Rosanne Model Ronald G. Landes Mary McEachron Kevin Perrott Carol Rayner Ron Viner

Frank and Barbro Greene Charitable Fund Hilary and Chris Hansen Marilyn and Bob Isherwood Paul Kefalides and Mark Neely Elinor A. and James E. Lacy Ragnhild and Knut Larssen R. Elton Leith Susan and David Mayer Jane Miller Susan Ohrenschall Becky and Jerry Oken Peggy Pennal Grace and Roland Perkins Margit and James Pettipas PG&E Corporation Foundation Virginia and Don Pierce

Elaine and Ken Chew

Andrea Schultz

Joseph Bodovitz

Patricia and Melford Chudacoff

Jackson Scott

Sydne and Allan Bortel

Carole Bennett and Norman Ciampi

Nancy and Robert Sellers

Nancy and N. Edward Boyce

Colleen and John Silcox

Toni and Gary Bramon

David Slate

Ute and John Brandon

Geraldine Messina Smith

Leanna Breese

Jenifer and John Smyth

Rachel Brem

Barbara and Harvey Sperry

Ruth Broady

Gary R. Spratling

Geraldine and Martin Brownstein

Arthur Cohen Bill Cope Greg Costopoulos Stone Coxhead S. Malvern Dorinson Catherine Doyle Sharon Early Maryann and John Elloway Lois B. Epstein, M.D., D.Sc. Jacqueline and Christian Erdman Judi and Fredric Finkelstein Alison Fuller

Diane L. and Edward A. Powell Fund

Elizabeth and Hugh Fullerton

Lois Prentice

Hugh Hagerty

Price Family Foundation

Anthia and Charles Halfmann

The George Sarlo Foundation

Gay and Wyman Harris

Hermann E. Schnabel

Evelyn Haupt

Audrey and Andrew Shapiro

Sunny Blende and Randy Hixon

Margaret C. and Lloyd H. Smith

Patricia and Joseph Gryson

Gabriella and Glenn Isaacson

Judy C. Webb

Soroptimists International of Novato

Diana and Theodore Jorgensen

Susan and Fritz Zimmer

Paul A. Spiegel

$1,000–$4,999

Joanne Smaciarz and Rodney Stock

Jan and Bill Kerr

Anonymous Tarek AbuZayyad Wanda R. Headrick and Hans Adler Scott B. and Annie P. Appleby Charitable Trust Bank of Marin Constance P. and Christopher C. Benz Jean and Stuart Brown Jeanne J. and William Cahill CaterMarin Jan King and John Clifford Phoebe Cowles Tareq Darwazeh Nathan and Violet David Foundation Nancy Marsh SangsterDe Haan and Robert De Haan Philip Economon Sally and Anthony Elshout Margot Fraser Fund The Geistlinger Family Trust Gary Giacomini

Aileen and Daniel Keegan

Vi Grinsteiner Strain and Dick Strain

Leslee and Roger Budge

Pauline L. and John G. Stuber

Mary Jane Burke

Diane and Paul Temple

Anne and John Busterud

Deborah and Timothy Terrill

Virginia S. Button

Michael A. Thompson

Judith Campisi

Sally Tilbury

Jeanne Carley

Lorraine Voskanian

Linda Carlson

Cristina and Terrence Wadsworth

Elizabeth Enemark and Theodore Carpenter

Cynthia Harrison Wallach

Birgit Chase

Donna and Richard Wallrich

Sylvia and Wallace Chipman

Susan Wheeler

Carolyn S. Ciampi

Christine and Paul Wichman

Nico Cinocco

Susan and Al Wilcox

Cheryl A. Clarke

Susan and Ian Wilson

Mimi and Peter Clarke

Carroll and George Yandell

Ann and Robert Clausen Christine Clausen

$1–$499

Nikki and Don King

Anonymous

Carmella Kramer

Diane and John Akers

Nancy and Dick Kuhn

Kathleen and Peter Allan

Evelyn Warren

K.C. and Steve Lauck

Catherine Amparano

Carine Zeeni and Joseph Antoun

Sharon and Kenneth Levien

Patricia Anderson

Nancy Lumer

Ann Andrews

BioMarin Pharmaceutical Inc.

Katie Torgerson and Ron Marley

Patsy and R. Howard Annin Jr.

Shirley McDonald

Elizabeth and James Austin

Charlotte S. and Donald F. Urban

$500–$999 Anonymous Active 20/30 Club of Santa Rosa #50 James Adams, M.D. and Carolyn Gracie, M.D. The Aguila Family Phyllis and Christian Baldenhofer Nancy Batt Francesca and Patrick Bell

Catherine and Ted McKown Lucinda Merrill Lillian J. and Bernie F. Mulaskey Merla Zellerbach and Lee Munson Hilda Namm Laurie Nardone Cheryl Finley-Neal and Barry Neal

Joan R. Bergsund

Patricia Gilbert and Jeremy Norman

Elaine and Lyman Black

Joyce Palmer

Boring Charitable Fund

Mandy and Sam Parke

Mary Jo Broderick

Kelley Baer and Louis Pozzo

Diane and Davis Brown

Jeanne W. Rathjens

Sally Buehler

Maryanne and Louis Ravano

Joan Capurro

Roberta and James Romeo

34 Buck Institute 2014 Annual Report

Wendy Buchen

Dawna and J. Dietrich Stroeh

Linda Armstrong Barbara and Larry Babow Marabeth Bacon Daniel Barajas Marina Zuk and Michael Barber Judith and Ron Barr Lawrence Bauer Robert Baughman Jane Gianino and Harold Baum Peggy and John Bell Mary Bersot Rose and Frank Bisbiglia Josephine and George Blagden Susan and Howard Blair Rosalind and David Bloom Helen Bodington

Connie Codding Ellie Corley Janice and Richard Cotton Cindee and Philip Crawley Judith and Robert Creasy Katherine and Tom Culligan Virginia Cunningham Kay and Warren Davis Patricia and Robert Dawson Jeanne DeJoseph and Suzanne Dibble Ann De Vogel Anne R. Delaney Thomas R. Delebo James DePeyster Shirley and Donald Diamond Dolores Dietz Jean Arnold and Tom Digulla Roberta Dillon Christine Dohrmann Marjorie and Jeron Donalds Mary and Kevin Dowling Sarah and Kenneth Drexler Roberta and Alan Dunham Roselee Dunlavy Elke and Vernon Dwelly Dianne M. Easton Ann Eckelhoff

honor roll of donors Delia F. Ehrlich Lisa M. Ellerby Audrey and Kenneth Ellingsen Marcia and Steve Ellis Charmaine Eng-Ngin Jean and Herbert Epstein John Erdmann Kathleen and Dick Eschleman Kristi Evans Margaret and Arthur Faibisch Leon Farley Elizabeth and Jim Ferguson Lisa Fialco Poppy H. Finston Arlis Fisk Judy Flowers Graham Forder Louisa and David Fraser Charles B. Freas Barbara and E.W. Fredell Wendell Freeman Vida Ray and Ted Freeman Madelon and Roger Fross

Karen Hemmeter and Robert Hall

Jan and Matt Lennon

Donna and Tom Oshel

Judith and Leonard Shaw

Fran and Walter Hall

Mike Leslie

Steve Page

Jeffrey Sheff

Kristine M. Leung

Kathleen and Alan Pallie

Alice and Michael Shiffman

Lorraine and Robert Levin

Norman H. Palter

Mary Shull

John Levinsohn

Claire and Simon Pass

Sybil Skinner

Sandra Levitan

Angelo Pastorino

Don and Jean Smith

Henry Levitan

Elaine and Darrel Snyder

Nyla and Aaron Levy

Patricia Conway and James Patten

Rosario Carr-Casanova and Richard E. Levy

Lynn and Richard Payne Teri Pearson

Cheryl and Gideon Sorokin

Judith and Robert Lewis

Gail and David Perin

Patricia and Lyle Lewis

Darlys and Thomas Perry

Linda Liscom

Donna and Jerry Peters

Victoria Lunyak and David Linton

Neil B. Peterson

Nancy Ellenbogen and Joel Lurie

Maria Pitcairn

Donna Halow Glenne Harding Jenifer Harris Anita and William Dennis Hassler Patricia J. Hassman Jo and Dean Heffelfinger Kay and Roger Heigel Emily and Robert Heller Mary Freer Hempel Rebecca and Robert Henn Judith and William Henry Patricia Hess Ann L. Heurlin Helen Morgan Hewitt Jorgen Hildebrandt Cindy Hill Mary M. Hofmann Hogan Land Services, Inc. Jean Howard Virginia and Don Humphreys

Samantha Lyons Jeanne and Patrick MacLeamy Burdette and Michael Maddalena Delphine and Dennis Mangan Diana and Kevin Mann Michelle Martino

Ken Petron Suzie G. Pollak Melissa Prandi Viacheslav Prokhorov Nancy Ragano Janet and Rudy Ramirez Phyllis and Steven Reinstein Shannon Reiter

Marie McKinney

Michele and Steve Rempe

Margaretha and Anthony Miglo

Harry Richardson Richard Robinson

Virginia Milano

Lynda Rodefer

Cindy Milano

Kathlyn and Rich Ronsheimer

Candiece and John Milford

Carma Rose

Dorothy and Arlen Mills

Linda Rosen

Barbara Millstein

Jay Rosenberger

Sally and Indru Mirchandani

Judith and David Rosner

Beverly and Carl Mitchell

Robert A. Roth

Laura Monterosso

Susan Rouder

Janie and Joseph Karp

Karen and William Morgenstern

Deborah and Herbert Rowland

Scott Kerr

Carol Mowbray

Kathy and Russ Ketron

Kathleen Mozena

Dixie J. Ruud

Delyn and Nicholas Kies

Kari and Hans Mueller

Mildred N. King

Margaret Murphy

Joan and Stanley Green

Norma King

Eileen W. Murray

Elizabeth and Joseph Greenberg

Marion and William Kleinecke

Janet Natov

Derek Knell

Gwen and Jim Neary

Barbro and Robert Gregory

Dipa Bhaumik and Vishwanath Koppaka

Cynthia and Manny Nestle

Verna and Jack Krout Maria Kuester

Madalienne F. Peters and Bix Newhard

Linda and Jim Kuhns

Jeanette F. Nichols

Ava and Sam Guerrera

Helen L. LaHaye

Eddie M. Nomura

Margie and David Guggenhime

Almon E. Larsh, Jr.

Thomas Novak

Anne Latta

Betty Obata

Janine Guillot and Shannon Wilson

Ann and Richard Laye

Glorraine Obertello

Colleen and Robert Haas

Judy and David Layne

Frances and Louis O’Brien

Sharon Leach

Ann W. Ocheltree

Judy and Robert Leet

Andrea and David Oppenheimer

Peggy and Bob Fujimoto Clara Pearl Fusco Solange and Andre Gabany Ellen White and Ronald Gaines Anita Gajewski Debi and James Galli Tom Gaman Betty E. Gandel Elizabeth and David Ganz Rita and Kent Gershengorn Patricia and Stewart Gittings Nina and John Gladish Betty and Jon Goerke Gail and Marc Goldyne Joanne Gordon Lorraine L. Grace

John Greif Shirley and Nelson Gremmels Sara G. Griffith Linda Grindel

Julie and Walter Haas Kevin Hagerty

Judy Hunt Lander and William Hynes Barbel and Gordon Jacobs Helene and Stephen Jaffe Michelle and Paul Jakab Wendy and Dean James Fanny and Heinrich Jasper Shirley Johnson Kay and David Jones Miriam and Edwin Kaegi Richard Kalish

Mardi Leland

Helen F. Neville

Dylis and Peter Sommer Gregory Spencer Jon and Maria Stark Susan and Richard Steinbach David and Vicki Stolberg Maureen Reyes and Jonathan Straw Sucherman Consulting Group, Inc. Shirley A. Sullivan Marcia and Timothy Taebel Katherine and Jay Taggart Marilyn and Irving Tallman Skipper and John Taylor Maureen and Paul Ter Beek Cindy and Mark Terrien Beatrice Levit and Al Thomas Berit Tisell Donald N. Tornberg Maureen Tresch Kurt Trutner Ewa Uding

Deanne Roy Margaret J. Salenger Haywood King and Bruce Sams Patricia Sanborn Barbara and Jules Schechner Kathleen and Bill Schlegel Inga and John Schmidt

Suzette Veluz Cathy Viscarra Lisa Volat George Wagner Barbara C. Wallace Russell Wallace Linda and Jeffrey Warren Martha and Douglas Watt David Weibel Joyce B. Wells Mary Jane Wets Nancy Wills Peggy and Charles Wilson

Carolyn Schorr

Janice and George Wissler

Nyra Krstovich and John Schrader

Suchitra Wong Gerry Zalkovsky

Gail Schroeder

Pat and Walt Zebrowski

Sally and Steven Schroeder

Jeannette Ziegler

Mary Barbara Schultz Virginia and William Schultz Jacqueline Sciarrillo Michele E. Scott SENS Foundation Susan Severin Brenda Shank Joan M. Shannon

Buck Institute 2014 Annual Report 35

As of June 30, 2014

ADMINISTRATION

FACULTY

B r ian K e n n e dy , P h D President and Chief Executive Officer

J u li e A n de rs e n ,

M ary M c E ach ron , JD Chief Administrative Officer and General Counsel

C h r i stoph e r B e nz ,

R aja K amal ,

PhD Senior Vice President for Institute Relations

M arti n B ran d ,

MD

PhD

D ale B r e de s e n ,

R e my G ross III Vice President, Business Development and Technology Advancement

J u dith C ampi s i ,

MD

MD, P h D

PhD

Professor

L i sa E lle r by ,

PhD Associate Professor

J e n n i fe r G ar r i son , Assistant Professor

PhD

PhD

P ejm u n H ag h ig h i , R ob e rt H ug h e s , H e i n r ich J as pe r ,

V ictor ia L u nyak ,

PhD

Associate Professor PhD

S i mon M e lov ,

PhD Associate Professor

PhD

S ean M oon ey ,

PhD

D avi d N icholls ,

Associate Professor

PhD Associate Professor

Vice President, Facilities and Planning

D avi d G r e e n b e rg ,

G or don L ithgow , Professor

Professor

Professor

R ach e l B r e m ,

PhD

Professor

Professor

N ancy D e r r

B radfor d G i bson , Professor

Professor

Vice President, Finance, and Chief Financial Officer

R alph O’R ear

PhD

Professor

Professor

P an kaj K apah i ,

PhD Associate Professor

B r ian K e n n e dy ,

PhD President and CEO, Professor

PhD Associate Professor PhD

Professor

A rvi n d R amanathan ,

PhD

Assistant Professor

X ian m i n Z e ng ,

PhD Associate Professor

D e e pak L amba ,

MBBS, P h D Assistant Professor

The courtyard at the heart of the Buck campus underwent a landscaping upgrade this year.

The work and landscape materials were donated

by Ghilotti Construction Company as part of their 100th anniversary celebration. The tulip trees and irrigation system were donated by members of the Buck Board of Trustees.

36  Buck Institute 2014 Annual Report

Design: Tobi Designs; Editor-in-Chief and Writer: Kris Rebillot; Content Strategist: Carlotta Duncan; Writer: Todd Plummer; Copy Editor: Virginia Kean; Photography: Richard Morgenstein, Robert Vente, Todd Plummer, and Leslie Belingheri; Project Manager: Leslie Belingheri; Proofer: Shannon Waite

buck staff

Buck Institute 8001 Redwood Blvd.

Novato, CA 94945 Tel: 415-209-2000 E-mail: info@buckinstitute.org www.buckinstitute.org

FPO